H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30 [Yahoo! Finance]
Does The Market Misread BioCryst Pharmaceuticals After DCF Upside And Low Sales Multiple In 2025? [Yahoo! Finance]
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at HC Wainwright from $30.00 to $32.00. They now have a "buy" rating on the stock.
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years [Yahoo! Finance]
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years